Analyzing Akebia Therapeutics (AKBA) and Evofem Biosciences (EVFM)

Akebia Therapeutics (NASDAQ:AKBA) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares Akebia Therapeutics and Evofem Biosciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akebia Therapeutics $177.98 million 2.51 -$76.91 million ($1.77) -4.43
Evofem Biosciences N/A N/A -$9.99 million N/A N/A

Evofem Biosciences has lower revenue, but higher earnings than Akebia Therapeutics.

Profitability

This table compares Akebia Therapeutics and Evofem Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akebia Therapeutics -30.60% -46.95% -17.53%
Evofem Biosciences N/A N/A -1,461.62%

Institutional & Insider Ownership

75.3% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 79.3% of Evofem Biosciences shares are held by institutional investors. 8.2% of Akebia Therapeutics shares are held by company insiders. Comparatively, 3.4% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Akebia Therapeutics has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of 2.85, meaning that its stock price is 185% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Akebia Therapeutics and Evofem Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics 0 1 6 0 2.86
Evofem Biosciences 0 0 5 0 3.00

Akebia Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 155.10%. Evofem Biosciences has a consensus price target of $10.40, indicating a potential upside of 162.63%. Given Evofem Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Evofem Biosciences is more favorable than Akebia Therapeutics.

Summary

Evofem Biosciences beats Akebia Therapeutics on 7 of the 11 factors compared between the two stocks.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

About Evofem Biosciences

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply